Abstract:The Hippo pathway plays a critical role in organ size control in development. Deregulation of the Hippo pathway leads to drastic enlargement of organs due to increased cell proliferation, inhibition of apoptosis, and dedifferentiation of differentiated cells. Interestingly, deregulation of the Hippo pathway also plays a critical role in tumorigenesis. However, precise roles of the Hippo pathway in tumorigenesis are unclear. By generating genetically defined liver tumor-initiating cells (TICs) with Hippo pathway inactivation or YAP activation, we found that the Hippo pathway unexpectedly mediates a crosstalk between TICs and the immune system. Via cytokines induced by YAP, TICs actively recruit M2 macrophages from as early as the single-cell stage. Elimination of TIC-associated macrophages (TICAMs) abolishes tumorigenesis in a manner dependent on the immune system. Furthermore, YAP activation has been observed in TICs induced by pathologically relevant oncogenes in murine livers and in human hepatocellular carcinoma (HCC) precancerous lesions. These results demonstrate for the first time that macrophages play a decisive role in the survival of single TIC in vivo and provide a proof of principle for TIC elimination by targeting YAP or M2 macrophages. Furthermore, we found that YAP induces leukocyte-specific integrin β2 (ITGB2) expression in cancer cells, thereby promoting cell invasion through the endothelium in a manner mimicking leukocytes. Through independent biochemical purification and a functional screen, we further identified PR/SET domain 4 (PRDM4) as a transcription factor interacting with the WW domains of YAP to mediate ITGB2 expression and cell invasion. Consistently, ITGB2 and PRDM4 mRNA levels are significantly increased in metastatic prostate cancer. In addition, PRDM4 contributes to YAP-induced tumorigenesis, possibly via mediating the expression of other YAP target genes. Our results demonstrate that YAP promotes cell invasion by inducing leukocyte-specific integrin expression and identify PRDM4 as a novel transcription factor for YAP targets. Citation Format: Xiaocan Guo, Huan Liu, Xiaolei Cao, Bin Zhao. The Hippo pathway in cancer [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr IA21.

Transmembrane Protein KIRREL1 Regulates Hippo Signaling Via a Feedback Loop and Represents a Therapeutic Target in YAP/TAZ-active Cancers.

Integrated screens uncover a cell surface tumor suppressor gene KIRREL involved in Hippo pathway

YAP/TAZ for cancer therapy: Opportunities and challenges (Review)

YAP/TAZ for Cancer Therapy: Opportunities and Challenges (Review).

Abstract IA21: the Hippo Pathway in Cancer

CRKL Enhances YAP Signaling through Binding and JNK/JUN Pathway Activation in Liver Cancer

Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase

The Hippo-YAP pathway: new connections between regulation of organ size and cancer.

TEAD Mediates YAP-dependent Gene Induction and Growth Control

Hippo Signalling Governs Cytosolic Nucleic Acid Sensing Through Yap/Taz-Mediated Tbk1 Blockade

EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1

Targeting Yap/Taz-Tead Protein-Protein Interactions Using Fragment-Based And Computational Modeling Approaches

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

Integration of Hippo Signalling and the Unfolded Protein Response to Restrain Liver Overgrowth and Tumorigenesis

A Coordinated Phosphorylation By Lats And Ck1 Regulates Yap Stability Through Scf Beta-Trcp

YAP represses the TEAD-NF-κB complex and inhibits the growth of clear cell renal cell carcinoma

Yap and Taz Take Center Stage in Cancer

Targeting the Hippo Pathway for Anti-cancer Therapies.

Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma

New insights into the ambivalent role of YAP/TAZ in human cancers

Emerging Role of Hippo-YAP (Yes-Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) Pathway Dysregulation in Renal Cell Carcinoma Progression